We are live on ! Find out more
NUVL

Nuvalent
NUVL

Delisted

NUVL was delisted on the 14th of July, 2026.

196 hedge funds and large institutions have $6.26B invested in Nuvalent in 2025 Q3 according to their latest regulatory filings, with 25 funds opening new positions, 74 increasing their positions, 61 reducing their positions, and 34 closing their positions.

New
Increased
Maintained
Reduced
Closed

21% more repeat investments, than reductions

Existing positions increased: 74 | Existing positions reduced: 61

14% more capital invested

Capital invested by funds: $5.49B → $6.26B (+$777M)

0.3% more ownership

Funds ownership: 108.31%108.62% (+0.3%)

0% more funds holding in top 10

Funds holding in top 10: 1010 (0)

6% less funds holding

Funds holding: 209196 (-13)

26% less first-time investments, than exits

New positions opened: 25 | Existing positions closed: 34

49% less call options, than puts

Call options by funds: $3.36M | Put options by funds: $6.66M

Holders
196
Holders Change
-13
Holders Change %
-6.22%
% of All Funds
2.57%
Holding in Top 10
10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.13%
New
25
Increased
74
Reduced
61
Closed
34
Calls
$3.36M
Puts
$6.66M
Net Calls
-$3.29M
Net Calls Change
-$1.64M
Name Holding Trade Value Shares
Change
Change in
Stake
DM
1
Deerfield Management
New York
$1.56B
Fidelity Investments
2
Fidelity Investments
Massachusetts
$866M +$3.51M +44,391 +0.4%
PBA
3
Paradigm Biocapital Advisors
New York
$456M
Vanguard Group
4
Vanguard Group
Pennsylvania
$398M +$6.39M +80,883 +2%
BlackRock
5
BlackRock
New York
$353M +$3.13M +39,539 +1%
Wellington Management Group
6
Wellington Management Group
Massachusetts
$199M +$57.3M +724,491 +46%
Janus Henderson Group
7
Janus Henderson Group
United Kingdom
$189M +$32.1M +406,093 +23%
T. Rowe Price Associates
8
T. Rowe Price Associates
Maryland
$157M +$1.19M +15,047 +0.8%
JP Morgan Chase
9
JP Morgan Chase
New York
$145M +$37.7M +476,822 +40%
State Street
10
State Street
Massachusetts
$136M +$6.68M +84,468 +6%
PA
11
Perceptive Advisors
New York
$135M +$14.8M +187,156 +14%
CC
12
Commodore Capital
New York
$121M +$1.98M +25,000 +2%
RCM
13
RA Capital Management
Massachusetts
$108M +$98.6M +1,246,456 New
VPC
14
Vestal Point Capital
New York
$95.1M +$1.98M +25,000 +2%
Geode Capital Management
15
Geode Capital Management
Massachusetts
$94.6M +$7.68M +97,148 +10%
WP
16
Woodline Partners
California
$92.5M +$13.1M +165,288 +18%
PCH
17
Polar Capital Holdings
United Kingdom
$88.4M +$16.3M +206,138 +25%
T. Rowe Price Investment Management
18
T. Rowe Price Investment Management
Maryland
$88.3M -$5.8M -73,332 -7%
B
19
Braidwell
Connecticut
$87.6M -$12.9M -162,894 -14%
FFM
20
Fairmount Funds Management
Pennsylvania
$62.9M
Adage Capital Partners
21
Adage Capital Partners
Massachusetts
$49.7M -$237K -3,000 -0.5%
Ameriprise
22
Ameriprise
Minnesota
$45.6M +$3.38M +42,707 +9%
Goldman Sachs
23
Goldman Sachs
New York
$38.4M -$7.2M -91,009 -17%
Charles Schwab
24
Charles Schwab
California
$35M +$4.59M +58,047 +17%
FTM
25
First Turn Management
California
$34.1M +$5.85M +73,956 +23%

NUVL Hedge Fund Activity: Q3 2025 in Review

196 of the 7,619 institutional investors tracked by Wall St. Rank reported a position in Nuvalent (NUVL) for Q3 2025, worth a combined $6.26B — up 14% from $5.49B a quarter earlier.

Sellers outnumbered buyers: 34 funds closed out of NUVL and 25 opened new positions — a net loss of 9 holders — while 61 trimmed existing stakes and 74 added.

The largest buyer was RA Capital Management, opening a new position worth an estimated $98.6M. The largest seller was Bain Capital Life Sciences Investors, exiting entirely with an estimated $110M sold.

  • 196 institutional investors held Nuvalent (NUVL) as of Q3 2025, down from 209 in Q2 2025.
  • Funds reported $6.26B of Nuvalent stock for Q3 2025, up 14% quarter-over-quarter.
  • 25 funds opened new Nuvalent positions in Q3 2025 and 34 closed out, a net change of -9 holders.
  • The largest Nuvalent buyer in Q3 2025 was RA Capital Management, an estimated $98.6M added.
  • The largest Nuvalent seller in Q3 2025 was Bain Capital Life Sciences Investors, an estimated $110M sold.

Based on aggregated 13F filings for Q3 2025.